Evidence map›Paper›PMID 30417070›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2018

Temporospatial components of brain ERPs as biomarkers for Alzheimer's disease.

Robert M Chapman, Margaret N Gardner, Rafael Klorman, Mark Mapstone, Anton P Porsteinsson, Inga M Antonsdottir, Lily Kamalyan

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Robert M ChapmanDepartment of Brain and Cognitive Sciences and Center for Visual Science at the University of Rochester, Rochester, NY, USA.
Margaret N GardnerDepartment of Brain and Cognitive Sciences and Center for Visual Science at the University of Rochester, Rochester, NY, USA.
Rafael KlormanDepartment of Clinical and Social Sciences in Psychology at the University of Rochester, Rochester, NY, USA.
Mark MapstoneDepartment of Neurology, University of California Irvine, Irvine, CA, USA.
Anton P PorsteinssonDepartment of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Inga M AntonsdottirDepartment of Brain and Cognitive Sciences and Center for Visual Science at the University of Rochester, Rochester, NY, USA.
Lily KamalyanDepartment of Brain and Cognitive Sciences and Center for Visual Science at the University of Rochester, Rochester, NY, USA.
University of Rochester · USUniversity of California, Irvine · US

Funding

VISUAL SCIENCE RESEARCH CTR SUPPORTP30EY001319 · NEI · UNIVERSITY OF ROCHESTER · PI Susana Marcos · 1985 to 2026
$17.5M
AD Pilot Clinical Trials: Spatiotemporal Brain ERP MeasuresR01AG041313 · NIA · UNIVERSITY OF ROCHESTER · PI CHAPMAN, ROBERT M · 2012 to 2016
$1.6M
Cognitive Brain Activity: Aging and DementiaR01AG018880 · NIA · UNIVERSITY OF ROCHESTER · PI CHAPMAN, ROBERT M · 2003 to 2007
$1.4M
NEI NIH HHS P30 EY001319NIA NIH HHS R01 AG018880NIA NIH HHS R01 AG041313
6 · The paper itself

Abstract

introductionDeveloping biomarkers that distinguish individuals with Alzheimer's disease (AD) from those with normal cognition remains a crucial goal for improving the health of older adults. We investigated adding brain spatial information to temporal event-related potentials (ERPs) to increase AD identification accuracy over temporal ERPs alone.

methodsWith two-step principal components analysis, we applied multivariate analyses that incorporated temporal and spatial ERP information from a cognitive task. Discriminant analysis used temporospatial ERP scores to classify participants as belonging to either the AD or healthy control group.

resultsTemporospatial ERPs produced a cross-validated area under the curve of 0.84. Adding spatial information through a formal procedure significantly improves classification accuracy. DISCUSSION: A weighted combination of temporospatial ERP markers performs well in detecting AD. Because ERPs are noninvasive and inexpensive, they may be promising biomarkers for AD that can add functional information to other biomarker systems while providing the individual's probability of correct classification.

Indexed as

AgingAlzheimer's disease (AD)Brain event-related potentials (ERP)Brain spatial informationDiagnosisDiscriminant analysisElectrophysiologyPosterior probabilitiesPrincipal components analysis (PCA)Receiver-operating characteristic (ROC)Temporal ERP componentsTemporospatial ERPsTwo-step PCA

Identifiers

PMID30417070
PMCPMC6215980
OpenAlexW2889161458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.